1 employees
Ascent Therapeutics offers Pepducins targeting GPCRs on the cell membrane, expanding the GPCR frontier.
2006
$19M
from 2 investors over 2 rounds
Ascent Therapeutics raised $19M on November 5, 2007
Investors: TVM Life Science Management Inc and HealthCare Ventures LLC